regulus therapeutics - Robuta Search

https://www.biospace.com/regulus-therapeutics-to-host-virtual-investor-event-on-september-6-2023 Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023 - BioSpace Aug 23, 2023 - Regulus Therapeutics Inc today announced that it will host a virtual investor event on Wednesday, September 6, 2023. regulus therapeutics investor event https://www.biospace.com/regulus-therapeutics-reports-first-quarter-2020-financial-results-and-recent-updates Regulus Therapeutics Reports First Quarter 2020 Financial Results and Recent Updates - BioSpace May 15, 2020 - Initiated Third and Final Cohort of the Multiple Ascending Dose Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease regulus therapeutics first quarter https://www.globenewswire.com/fr/news-release/2025/04/30/3071213/0/en/Novartis-to-acquire-Regulus-Therapeutics-and-farabursen-an-investigational-microRNA-inhibitor-to-treat-ADPKD-the-most-common-genetic-cause-of-renal-failure.html Novartis to acquire Regulus Therapeutics and farabursen, an Regulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics with a focus on autosomal dominant polycystic kidney disease... to acquire regulus therapeutics novartis https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-timing-for-second-quarter-2021-financial-results-webcast-and-conference-call-301347375.html Regulus Therapeutics Announces Timing for Second Quarter 2021 Financial Results Webcast and... /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines... financial results webcast regulus therapeutics second quarter https://www.biospace.com/regulus-therapeutics-inc-to-ring-the-b-nasdaq-b-stock-market-closing-bell Regulus Therapeutics, Inc. To Ring The Nasdaq Stock Market Closing Bell - BioSpace the nasdaq stock market regulus therapeutics inc https://www.biospace.com/regulus-therapeutics-announces-first-patient-dosed-in-third-cohort-of-phase-1b-multiple-ascending-dose-mad-clinical-trial-of-rgls8429-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending... Nov 2, 2023 - Regulus Therapeutics Inc. today announced the dosing of the first patient in the third cohort of the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. https://www.insidermonkey.com/blog/13g-filing-biotechnology-value-fund-lp-and-regulus-therapeutics-inc-rgls-579431/ 13G Filing: Biotechnology Value Fund LP and Regulus Therapeutics Inc. (RGLS) - Insider Monkey You can access the original SEC filing by clicking here. regulus therapeutics inc https://www.benzinga.com/trading-ideas/long-ideas/22/01/25257681/5-penny-stocks-insiders-are-buying-opgen-regulus-therapeutics-and-more 5 Penny Stocks Insiders Are Buying: OpGen, Regulus Therapeutics And More - Crexendo (NASDAQ:CXDO),... Jan 27, 2022 - The US economy grew 6.9% on quarter during the last three months of previous year, up from 2.3% expansion in the prior quarter and also above market estimates... https://www.biospace.com/regulus-therapeutics-inc-release-all-hcv-patients-treated-with-a-single-sc-administration-of-4-mg-kg-of-rg-101-responded-with-mean-viral-load-reduc Regulus Therapeutics, Inc. Release: All HCV Patients Treated with a Single SC Administration Of 4... https://www.newswire.ca/news-releases/aptuit-announces-strategic-provider-agreement-with-regulus-therapeutics-627205411.html Aptuit Announces Strategic Provider Agreement with Regulus Therapeutics /CNW/ - Dr. Jonathan Goldman, CEO, Aptuit LLC, announced a strategic provider relationship between Aptuit, a leading Partnership Research Organization, and... provider agreement announces strategic regulus therapeutics https://www.insidermonkey.com/blog/regulus-therapeutics-rgls-one-of-the-best-short-term-stocks-to-buy-right-now-1484758/ Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now - Insider Monkey We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at where Regulus Therapeutics Inc. https://www.benzinga.com/25/04/45105514/novartis-to-buy-us-kidney-drug-developer-regulus-therapeutics-for-around-800-million Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million - Novartis... Apr 30, 2025 - Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to close in H2 2025.